Analyst Price Targets — AXGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 2:43 pm | Jayson Bedford | Raymond James | $41.00 | $35.00 | TheFly | AxoGen price target raised to $41 from $36 at Raymond James |
| February 19, 2026 10:50 am | — | Wells Fargo | $40.00 | $35.25 | TheFly | AxoGen initiated with an Overweight at Wells Fargo |
| December 5, 2025 4:01 pm | — | H.C. Wainwright | $39.00 | $33.70 | TheFly | AxoGen price target raised to $39 from $26 at H.C. Wainwright |
| December 5, 2025 11:41 am | — | Canaccord Genuity | $37.00 | $32.86 | TheFly | AxoGen price target raised to $37 from $27 at Canaccord |
| December 4, 2025 3:02 pm | Jayson Bedford | Raymond James | $36.00 | $33.19 | StreetInsider | AxoGen, Inc. (AXGN) PT Raised to $36 at Raymond James |
| December 4, 2025 1:47 pm | Frank Takkinen | Lake Street | $40.00 | $32.10 | TheFly | AxoGen price target raised to $40 from $30 at Lake Street |
| December 4, 2025 12:32 pm | — | Jefferies | $36.00 | $28.33 | TheFly | AxoGen price target raised to $36 from $29 at Jefferies |
| December 1, 2025 10:50 am | — | Mizuho Securities | $40.00 | $28.65 | TheFly | AxoGen initiated with an Outperform at Mizuho |
| October 30, 2025 3:40 pm | — | H.C. Wainwright | $26.00 | $22.86 | TheFly | AxoGen price target raised to $26 from $25 at H.C. Wainwright |
| October 30, 2025 10:25 am | — | Canaccord Genuity | $27.00 | $22.25 | TheFly | AxoGen price target raised to $27 from $24 at Canaccord |
Latest News for AXGN
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Gross margin compression is driven by one-time regulatory costs and biologics…
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.
This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.
First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AXGN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.